Loh, Mei Teng
Eli Lilly (United States)
2 papers on CoChat
Most cited papers
- Verified
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
Urva, S., Coskun, T., Loh, M. T., Du, Y., Thomas, M. K., Gurbuz, S., Haupt, A., Benson, C. T., Hernandez-Illas, M., D’Alessio, D. A., et al. (2022) · The Lancet
Diabetes Treatment and ManagementDiabetes Management and Research
Cited by 202
- Verified
The novel GIP , GLP ‐1 and glucagon receptor agonist retatrutide delays gastric emptying
Urva, S., O'Farrell, L., Du, Y., Loh, M. T., Hemmingway, A., Qu, H., Alsina‐Fernandez, J., Haupt, A., Milicevic, Z., & Coskun, T. (2023) · Diabetes, Obesity and Metabolism
Gastrointestinal motility and disordersDiabetes Treatment and Management
Cited by 28
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free